Forgot your password?

Forgot your username?

database > company
Gloucester Pharmaceuticals
Biotech Specialty Pharma
One Broadway, 14th Floor
Cambridge, MA 02142 USA
phone:617-583-1300
fax:617-583-1368
Symbol
Exchange
Founded
Employees
www.gloucesterpharma.com
Research Sector Biotech Specialty Pharma
Summary Description
Biopharmaceutical company focuses on the acquisition of oncology drug candidates.
Management
Alan Colowick, M.D., Chief Executive Officer ; Jean Nichols, Ph.D., President and Chief Operating Officer; Nicholas Vrolijk, Ph.D., Senior Vice President, Manufacturing Operations; Jeff Jonker, Vice President, Business Development and Corporate Strategy; Andy Strayer, Pharm.D., Vice President, Clinical Operations; Elizabeth Faust, Ph.D., Senior Director, Medical Affairs; Denise Hayes, M.S., M.B.A., Senior Director, Regulatory Affairs and Quality; Brian Wiley, Senior Director, Marketing and Business Development
Ownership
Financials Mkt Cap :
* numbers in thousands
 
Keywords
cancer, lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphoma

Comment | Printable Version | Modify profile |
Updated: Dec. 07, 2009

Description
Gloucester Pharmaceuticals is a privately held biopharmaceutical company that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first drug, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, was approved in November 2009 by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The Company is also conducting a registration trial in peripheral T-cell lymphoma (PTCL) with an anticipated sNDA filing in 2010 for this indication. Additional studies in both hematologic and solid tumors are currently ongoing. ISTODAX is approved for the treatment of CTCL and is not approved for the treatment of PTCL or other indications. Gloucester retains worldwide exclusive rights to ISTODAX.